Vericel (VCEL) Other Operating Expenses (2011 - 2025)

Vericel (VCEL) reported Other Operating Expenses of $22.3 million for Q2 2025, up 2.36% sequentially from $21.8 million in Q3 2024.

Vericel (VCEL) Other Operating Expenses (2011 - 2025) Analysis & Trends

Vericel (VCEL) has 7 years of Other Operating Expenses data on file, last reported at $22.3 million in Q2 2025.

For the quarter ending Q2 2025, Other Operating Expenses changed N/A year-over-year to $22.3 million; the trailing twelve-month figure through Mar 2026 stood at $22.3 million (up 2.36% YoY), and the FY2023 full-year result was $69.0 million, changed N/A from the prior year.
Other Operating Expenses grew to $22.3 million in Q2 2025, from $21.8 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $69.0 million in Q4 2023 to a low of $19.4 million in Q1 2024.
A 3-year average of $33.1 million and a median of $22.0 million in 2024 frame the typical range for Other Operating Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Vericel	2.30 Bn	2.15 Bn	49.27 Mn

Download Data